{
    "nctId": "NCT03592771",
    "briefTitle": "THRIVE Breast Cancer App Study",
    "officialTitle": "Communication App to Manage Symptoms and Improve Adjuvant Endocrine Therapy Adherence",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasm Female",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 304,
    "primaryOutcomeMeasure": "Adjuvant Endocrine Therapy (AET) Medication Adherence",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult female patients (age\u226518)\n* Diagnosis of ductal carcinoma in situ or Stage I-III hormone receptor-positive breast cancer\n* New prescription for an aromatase inhibitor or tamoxifen\n* Have a mobile device with a data plan or a home computer with Internet\n* Have a valid email address\n* Willing to complete brief surveys on a web-enabled device\n* AET is indicated as standard of care\n\nExclusion Criteria:\n\n* Unable to communicate in English\n* Prior use of adjuvant endocrine therapy (aromatase inhibitor or tamoxifen) for current diagnosis\n* Concurrently undergoing surgery, chemotherapy or radiation\n* Current diagnosis of rheumatoid arthritis\n* Chronic daily narcotic usage\n* Patient plans to move or transfer their care within the next year",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}